Showing results (1181-1190 of 4,634) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|January 25, 2021
Long noncoding RNA KTN1 antisense RNA 1exerts an oncogenic function in lung adenocarcinoma by regulating DEP domain containing 1 expression via activating epithelial-mesenchymal transitionYan-Yi Li, Wen Li, Guang-Zhe Chang, et al.
Anti-Cancer Drugs|February 3, 2021
Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatmentsRoberto Castelli, Antonio Gidaro, Giorgio L Deliliers, et al.
Anti-Cancer Drugs|February 3, 2021
Exceptional response to cyclophosphamide and dexamethasone in a patient with metastatic castrate-resistant prostate cancer and RB1 mutationBriana Dohogne, Hina Arif-Tiwari, Erika Bracamonte, et al.
Anti-Cancer Drugs|January 19, 2022
Lidocaine hampers colorectal cancer process via circITFG2/miR-1204/SOCS2 axisHuashe Wang, Xuexia Zhang, Yi Li, et al.
Anti-Cancer Drugs|January 2, 2022
LncRNA GAS5 promotes abdominal aortic aneurysm formation through regulating the miR-185-5p/ADCY7 axisYulong Wang, Shuiting Zhai, Jianwu Xing, et al.
Anti-Cancer Drugs|April 18, 2008
Capecitabine: an overview of the side effects and their managementMuhammad Wasif Saif, Nikos A Katirtzoglou, Kostas N Syrigos
Anti-Cancer Drugs|April 18, 2008
Hyperbilirubinemia's protective effect against cisplatin nephrotoxicity in the Gunn ratKarri Barabas, Rowan Milner, James Farese, et al.
Anti-Cancer Drugs|April 18, 2008
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001Michael Hejna, Markus Raderer, Johannes Zacherl, et al.
Anti-Cancer Drugs|April 18, 2008
Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinomaSarah-Jane Dawson, Nelly Marmy Conus, Guy C Toner, et al.
Anti-Cancer Drugs|October 15, 2009
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunitiesHelmout Modjtahedi, Sharadah Essapen
Pageof 464